Physician profile
Cheryl Smith
NPI 1396037966
$68,436.25
in general payments reported to CMS, 2019-2025
53 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,890 · 2020: $16.26 · 2021: $2,902 · 2022: $1,879 · 2023: $6,018 · 2024: $24K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $9,883 · Travel and Lodging: $6,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,945.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,580.00 |
| Food and Beverage | $9,882.77 |
| Travel and Lodging | $6,342.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $27,099.95 | 2021-2025 | Ultomiris |
| Ucb, INC. | $21,984.61 | 2023-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Argenx US, INC. | $8,144.15 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Catalyst Pharmaceuticals, INC. | $3,896.38 | 2019-2025 | |
| Abbvie INC. | $1,652.72 | 2022-2025 | Botox, Ubrelvy, Duopa |
| Mdd US Operations, LLC | $488.59 | 2022-2024 | Gocovri, Gocovri |
| Pfizer INC. | $426.34 | 2022-2025 | |
| Lilly USA, LLC | $385.99 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Lundbeck LLC | $311.27 | 2022-2025 | Vyepti, Rexulti |
| Biogen, INC. | $300.10 | 2021-2025 | Tysabri, Vumerity, Spinraza |
| Emd Serono, INC. | $262.97 | 2022-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $259.83 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $252.70 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $249.86 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $231.55 | 2023-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $226.24 | 2023-2024 | Wakix |
| Tanabe Pharma America, INC. | $216.54 | 2021-2025 | Radicava |
| Kyowa Kirin, INC. | $201.97 | 2023-2024 | Nourianz |
| Impel Pharmaceuticals INC. | $195.22 | 2023 | Trudhesa |
| Csl Behring | $180.45 | 2023-2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $168.52 | 2023-2024 | Nuedexta, Rexulti |
| Neurelis, INC. | $152.95 | 2022-2025 | Valtoco |
| Octapharma USA, INC. | $93.18 | 2023-2025 | Panzyga |
| Corium, LLC | $83.02 | 2023 | Adlarity |
| Grifols USA, LLC | $73.05 | 2024 | Gamunex-C |
| Averitas Pharma INC. | $67.51 | 2023-2024 | Qutenza |
| Ge Healthcare | $67.10 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $65.50 | 2023-2024 | Lumryz |
| Axsome Therapeutics, INC. | $54.79 | 2025 | Sunosi |
| Celgene Corporation | $47.37 | 2023-2025 | Zeposia |
| Idorsia Pharmaceuticals US INC | $46.91 | 2024-2025 | Quviviq, Quviviq |
| Medtronic, INC. | $44.94 | 2023-2025 | Percept PC Brainsense, Inceptiv |
| Biohaven Pharmaceutical Holding Company LTD. | $40.92 | 2022 | |
| Jazz Pharmaceuticals INC. | $40.46 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $35.51 | 2024 | Belbuca |
| Revance Therapeutics, INC. | $34.23 | 2024 | Daxxify |
| Genzyme Corporation | $33.20 | 2024 | |
| Azurity Pharmaceuticals, INC. | $29.69 | 2023 | Horizant |
| Boston Scientific Corporation | $29.12 | 2025 | Wavewriter Alpha Prime 16 |
| Merz Pharmaceuticals, LLC | $28.62 | 2025 | Xeomin |
| Janssen Scientific Affairs, LLC | $26.84 | 2024 | |
| Amgen INC. | $26.25 | 2025 | Uplizna |
| Strongbridge US INC. | $25.89 | 2019 | |
| Xeris Pharmaceuticals, INC. | $23.85 | 2023 | Keveyis |
| Impel Pharmaceuticals LLC | $23.57 | 2024 | Trudhesa |
| C2n Diagnostics, LLC | $22.63 | 2025 | Precivityad2 |
| Philips North America LLC | $16.26 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.89 | 2022 | |
| Eisai INC. | $14.11 | 2023 | |
| Acorda Therapeutics, INC | $13.89 | 2023 | Ampyra, Inbrija |
| Amylyx Pharmaceuticals, INC. | $12.89 | 2023 | Relyvrio |
| Akcea Therapeutics, INC. | $11.16 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.